Ning Yan

- Responsible for developing medical education, external engagement, internal training, and scientific communications strategy, establishing scientific platforms, and implementing SE&C plans to support global launch of breakthrough biologic therapy for immunologic indications. - Contributing to medical plan and leading medical communication plan by managing strategic alignment with external partners and internal stakeholders, KOLs and vendors/agencies for data dissemination, content presentation, and development of high-quality, fair-balanced, scientifically/clinically accurate, and compliant publication & communication deliverables. - Led MSLs in performing competitive intelligence gathering of medical congresses, managing medical booth exhibition content, meet-the-expert sessions, and interaction with HCPs, and providing feedback and insights to senior management; trained MSLs on key topics, scientific engagement, and competitive insights. - Won Innovation Challenge prize and led the innovation project funded by the CMO office to develop an AR-based novel educational app for field engagement with HCPs. Initiated digital projects for multi-channel approach that include video abstracts, animation videos, interactive ppt and pdf documents, infographics, external-facing website, live program enduring, navigate eBlasts, and supplemental publications for effective engagement with and extended reach for HCPs. One of such approaches with a reviewing article, an infographic, and an eBlast reached more than 26,000 HCP specialists.

- Managed oncology franchise communication plan and tactics in supporting clinical, medical, HEOR, and KOL strategy for solid tumor and blood cancer categories, and leading evidence generation, budget and vendors, and publication projects across brands. - Supported 5 oncology products, 2 biosimilars assets, and one medical device product.

- Define the global medical strategies for new product development: Partner collaboratively with cross-functional stakeholders to execute integrated plan including publication management, data dissemination, medical education and brand readiness; Establish benchmark knowledge and optimize resource allocation; Develop and maintain relationships with KOLs; Serve as the global medical interface to optimize medical strategies that align with regional timelines for market entry.

- New business development and client relationship management: Preparation and delivery of capability presentation, business proposal, and project execution; Led projects on biologic and small molecule assets that include PD1 antibodies, antibody-drug-conjugates, and target therapies, established relationship with asset holders and potential stakeholders, and managed negotiation and transaction.

─ Newly created position to initiate medical communications supporting all brands and franchises at PCH: Functioned in the capacity of medical affairs which include medical strategy, labeling and claims, safety assessment and pharmacovigilance, epidemiology and outcome, medical information and marketing, and medical education and communications. Established medical communication strategy planning and process excellence; developed SOP compliance and training programs, managed eight publication subcommittees for the assets in pain, respiratory, personal care, nutritional supplements, medical device, and Rx-to-OTC switches, and delivered on complex tasks within timeframe and by milestone achievement. Initiated vendor support, achieved internal alignment with franchise and commercial, prioritized resources and managed multimillion dollar budget; initiated promotional educations and executed the first Product Theater at PCH as medical marketing vehicle to promote global brands; implemented medical communication platforms effectively supporting new claims, brand objective, and marketing campaign. Initiated MSL program by reaching out to business owners for guidance and by identifying resources, regulations, performance measures, and enable technologies to establish field-based medical affairs function to support new product launch; generated product manuals, toolkits, and training decks that were well received as valuable references. Managed KOLs for medical communications, organized joint publication committee with business alliance partner, promoted cross-functional cooperation, and was regarded as resourceful, articulated, goal oriented, and pleasant to work with.

─ Strategic marketing & business development with P&L & people management responsibility in CRO space: Responsible for marketing strategy and commercial operations, new service and product launch, business and alliance development, customer engagement and relationship building, and review and approval of pricing, advertisement, press release, promotional materials, sales and field training, supported by a team of marketing managers and analysts and with multimillion budget. Led the development of corporate branding, business proposition, key messages, new service and product positioning, distribution channels, competitive intelligence, creative services, website redesign, email campaign, market analysis, and innovative promotions, resulting in achieving company’s goal in 2009 and 2010. Organized pipeline strategic planning and recommended 100 oncology targets, new assays, and new platforms such as offering custom antibody and biologics production service, identifying and licensing enabling technologies, and establishing partnership with external stakeholders, which increased the capability and capability without significant increase in resources. Established professional relationships and broad range collaborations with prestige academic institutions and industry enterprises such as MIT Broad Institute, Harvard Medical School, Mass General Hospital, Human Genome Sciences, Coca-Cola, DuPont, Pioneer, etc. through education and value proposition; delivered presentations on needs for value-added CRO services to potential clients and on rationale for new or expanded services to existing customers; secured $5M investment to the company for establishing a new business unit.

─ Medical & clinical strategy and communications with business impact on marketed & launching GI products: As global brand team member, contributed to brand strategy, medical plan, life cycle, clinical insights, and communication platform for supporting marketed PROTONIX for erosive GERD and for launching RELISTOR for opioid-induced constipation, through management of KOLs and alignment with business partners, internal colleagues and regional affiliates in global capacity; was promoted to director II. Directed communication programs pertinent to brand strategy, standard of care, scientific message, and unmet needs in GI, metabolism, and palliative care in advanced illness such as cancer patients; integrated publications into life cycle strategy and global medical plan, resulting in pivotal data publications in NEJM & top tier journals prior to the launch. Working with KOLs, contributed to study design, identified clinical studies, and led cross-functional team for post-hoc safety, efficacy, and quality of life analyses resulting in key findings based on e.g. adverse event case report form, rescue medication use, and dose response rate for pricing strategy and product positioning in regulatory filing and proposition for payer/managed care; commissioned health outcome researches leading to key messages for new marketing campaigns; developed scientific interpretation for timely dissemination of scientific information, resulting in large numbers of publications targeting diverse audiences in global reach. Critically provided medical review of clinical, regulatory, promotional, educational materials for accuracy and fair balance effectively supporting NDA, new claims, marketing campaign, and public relations; contributed to the development of training materials, literature summary, and scientific background for internal staffs and MSL teams.

─ Innovative promotional & educational communications primarily on respiratory & hepatitis diseases: Developed comprehensive, integrated, strategic promotional & medical educational campaigns through clinical data dissemination, diagnosis and treatment algorithm interpretation, medical literature research, faculty and KOL interaction, and corporate goal alignment; performed need assessment and awarded grants for live events, enduring outreach, and online learning; designed pre & post activity and accredited CE programs. Developed and executed innovative medical marketing programs, focusing on strategy and content development for CME symposia, dinner seminar series, consultant meetings, faculty training, and new business development; Developed review paper with Dr. Robert Gish on HCC challenges and management, and with Dr. Angela Falany on Hyperhomocysteinemia in Women. Contributed to several advisory boards on assessing effect of inhaled corticosteroids as new treatment option for asthma on PK/ADME, safety and efficacy, children’s development, and on cataract. Therapeutic area focus: oncology and liver cancer, respiratory and asthma, ophthalmology, infectious, hepatology and hepatitis, psychiatric, pain, metabolic and cardiovascular, and insomnia.

─ Promotional medical marketing primarily on infectious, oncology & CNS delivered in live & print globally: Provided scientific and strategic directions to ensure all medical communication and promotional programs were implemented to the highest standards exceeding clients’ expectation. Developed communication strategy and publication plan, SWOT and competitive analyses, key messages, primary and review manuscripts, abstract and poster presentations, case studies, training slide kits, workbooks, conference agenda, learning objectives, newsletters and conference coverage, and executive summary; the work included Medical Director Colloquy and P&T Digest. Contributed to re-accreditation for continuing medical, pharmaceutical, and nurse education (CME, ACPE, and CNE); responsible for timely review and approval of educational, promotional, and enduring materials for medical marketing and communications. Organized medical educational symposia and consultant meetings through content oversight, safety and efficacy assessment, client and KOL interaction, advocacy and faculty liaison; accomplished an Asia advisory board meeting with KOL recruitment in short lead time which positively impacted client’s late stage clinical strategy. Disease area focus with screening, diagnosis, and therapy on: oncology and hematology, infectious diseases, respiratory, inflammation, neurology and bipolar depression, cardiovascular and diabetes, transplant and transfusion, orthopedic surgery, dermatology, nephrology, and ophthalmology.